Trial Profile
A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid) in Chemotherapy-Naive Androgen-Independent Prostate Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 03 Aug 2010 Planned number of patients changed from 25 to 35 as reported by ClinicalTrials.gov.
- 03 Aug 2010 Planned end date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 05 Mar 2010 Preliminary efficacy and tolerability results were presented at the ASCO 2010 Genitourinary Cancers Symposium.